A carregar...
Dose Characterization of the Investigational Anticancer Drug Tigilanol Tiglate (EBC-46) in the Local Treatment of Canine Mast Cell Tumors
Mast cell tumor (MCT) is the most common cutaneous neoplasm in dogs and wide surgical resection is the current first-line treatment. However, recurrence is common and often requires more specialist and expensive therapies. Tigilanol tiglate is a novel small molecule drug delivered by intratumoral in...
Na minha lista:
| Publicado no: | Front Vet Sci |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6499228/ https://ncbi.nlm.nih.gov/pubmed/31111038 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fvets.2019.00106 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|